絞り込み

16644

広告

ウミガメにセンサー 海水温長期予測の精度「劇的向上」 (NHK)

ウミガメに水温のセンサーを取り付けてデータを集め、長期的な海水温の予測の精度を高めるユニークな手法を海洋研究開発機構などが開発しました。 気象の長期的な予報には...

  1. 古代エジプト人が頭に載せた謎の物体、つい...
  2. 香港デモ半年、日本人写真家が見た若者たち...
  3. オスマン帝国の600年、巨大帝国はこうし...
  4. 15世紀末の歯ブラシに使われていた動物の...

ニュース一覧

「"Kipps TJ"[Author]」の検索結果

410件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Targeted Therapy in Chronic Lymphocytic Leukemia.

Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia.

Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-κB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia.

A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

HNRNPL Restrains Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります